OCT has initiated a new clinical trial of monoclonal antibodies.
This is a single-center, comparative, randomized, double-blind study evaluating the pharmacokinetics, immunogenicity, and safety of a single intravenous administration of a daratumumab biosimilar compared to the originator drug. The study will be conducted in healthy volunteers. A total of 132 participants are planned to be recruited within a single center.
OCT is responsible for a wide range of services, including feasibility, site selection and management, project management, regulatory, and logistics.
